Open AccessPharmacotherapy in the Treatment of Obesity
Author(s) -
Floriana Elvira Ionică,
Simoegreș,
Oana Cristina Şeremet,
Cornel Chiriţă
Publication year - 2016
Publication title -
romanian journal of diabetes nutrition and metabolic diseases
Language(s) - English
Resource type - Journals
eISSN - 2284-6417
pISSN - 2068-8245
DOI - 10.1515/rjdnmd-2016-0048
Subject(s) - medicine , obesity , pharmacotherapy , dyslipidemia , fatty liver , intensive care medicine , diabetes mellitus , nonalcoholic fatty liver disease , disease , endocrinology
Background and Aims: In the last three decades, obesity and its related co morbidities has quickly increased. Sometime, obesity was viewed as a serious health issue in developed countries alone, but now is recognized as a worldwide epidemic, and its associated costs are enormous. Obesity is related with various diseases, like hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, chronic cardiovascular diseases, respiratory conditions, alongside chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This review purpose is to provide data on the current anti-obesity drugs, also available and in the development. Material and Methods: We searched MEDLINE from 2006 to the present to collect information on the anti-obesity pharmacotherapy. Results and Conclusions: In the patients with obesity related comorbidities, there may be an adaptation of the anti-obesity pharmacotherapy to the patients’ needs, in respect to the improvements of the cardiometabolic parameters. Although their efficacy was proven, the anti-obesity pharmacotherapies have presented adverse events that require a careful monitoring during treatment. The main obstacle for approve new drugs seems to be the ratio between the risks and the benefits, because of a long-time background of perilous anti-obesity drugs